flecting real-life clinical practice based on structured interviews with experts. METHODS: Six experts in the field of schizophrenia from different treatment settings and regions in Germany were consulted. Structured interviews about the treatment patterns and costs in selected outpatient and inpatient treatment areas, e.g. psychiatrists, occupational therapists, day care units and acute psychiatric wards, were conducted. Costs were assessed from the perspective of the state health insurance and compared to the costs associated with severe mental illness in an inpatient rehabilitation center. The results of the structured expert interviews will be used as input for cost-effectiveness models in schizophrenia. In further studies the results should be verified in real-life clinical practice.

PMH19
A rehabilitation intervention to help people with severe mental illness obtain and keep a paid job: the economic evaluation
Stant A1, Van Busschbach J2, Mochon H3
1University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 2Robert Coop Research Center, Groningen, The Netherlands, 3Frimois Institute, Utrecht, The Netherlands
OBJECTIVES: Only few people with severe mental illness are able to obtain paid work. Individual placement and support (IPS) is a vocational rehabilitation intervention that is associated with severe mental illness in finding employment. This study assessed the balance between costs and outcomes of IPS compared to regular vocational rehabilitation in people with severe mental illness in the Netherlands. METHODS: An economic evaluation was conducted alongside a multicenter RCT with a follow-up of 30 months. In total 153 people with severe mental illness were randomly assigned to IPS or regular vocational rehabilitation (RVR). The primary outcome measure of the cost-effectiveness analysis was the percentage of people with at least one day of paid work during the study. The economic evaluation was conducted from a societal perspective. Costs and outcomes were prospectively assessed during 30 months. The expectation maximisation algorithm with a bootstrap approach was applied to deal with missing cost data. RESULTS: The percentage of people with paid work during the study was significantly higher in the IPS group (44% versus 25% in RVR). There were no differences between groups in quality of life. Mean total costs were €57,285 in the IPS group and €43,819 in the RVR group. Cost types that contributed considerably to the total costs were related to hospital admissions, sheltered accommodations, and informal care. The calculated incremental cost-effectiveness ratio was €1,084 per cent of people with paid work gained. CONCLUSIONS: The study demonstrated that IPS was associated with higher costs and better (work-related) outcomes in people with severe mental illness. Decision makers will eventually have to decide whether the additional costs associated with IPS are worth the additional costs. Generalizing current results to other countries may only be possible after carefully comparing the various components of each health care system concerned.

PMH20
METABOLIC CONSEQUENCES AND COST-EFFECTIVENESS OF ASENAPINE IN THE TREATMENT OF Bipolar disorder
Solya Hammer C1, Portocarrero A3, Muciño-Ortega E1
1University of Toronto, Toronto, ON, Canada, 2Janssen Cilag, Birkerød, Denmark, 3Customized Premium Products S.A. de C.V., Mexico
OBJECTIVES: Many people suffering from bipolar disorder experience significant side effects of antipsychotics. The cost-effectiveness of asenapine compared to other atypical antipsychotics has not been assessed to date. METHOD: We performed a cost-effectiveness analysis of asenapine compared to other atypical antipsychotics (LAI) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OLZ-LAI) and risperidone (RIS-LAI) in 87.8%.

PMH21
A COST-EFFECTIVENESS OF INTRAMUSCULAR ZIPRASIDONE FOR THE TREATMENT OF ACUTE PSYCHIATRIC ASSESSMENT IN MEXICO
Galindo-Suárez BM1, Peniche-Otero G2, Herrera-Rojas J2, Baeza-Cruz G2, Nencleares-Cadavieco F1, Malmlo-Ortega E1
1Psychiatric Hospital Sveti Ivan, Zagreb, Croatia, 2Psychiatric Hospital, Birkerød, Denmark, 3Frimois Institute, Utrecht, The Netherlands
OBJECTIVES: The study is aimed to estimate the pharmacoeconomic profile of intramuscular injections of haloperidol 5mg, olanzapine 10mg and ziprasidone 20mg for acute agitation episodes associated with schizophrenia, schizoaffective disorder, or bipolar disorder in Mexican public health institution. METHODS: A discrete event simulation model was developed. The measure of effectiveness was the average time in which patients reach control ≥50%, regarding baseline level in the Overt Aggression Scales, with a time horizon of 12 hours. Clinical efficacy was extracted from published literature. A panel of experienced psychiatrists (n=12) was used to estimate the medical resource use profile. The model assesses direct medical costs (2012 US$) such as drugs, specialist’s visits, laboratory tests and management of adverse events. The results are reported in terms of ICER. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: The cost per patient for ziprasidone was €693, it represents €198.6 and €64.6 less than the cost of haloperidol and olanzapine, respectively. Differences in costs were driven by less specialist’s visits with ziprasidone and high incidence of akathisia and dystonia with haloperidol. The effectiveness model was accomplished by ziprasidone, olanzapine and haloperidol at 1.55h, 1.48h and 1.74h, respectively. Both ziprasidone and olanzapine dominated haloperidol. Results were robust to changes up to ±10% in the acquisition cost of ziprasidone. In probabilistic sensitivity analysis, results were consistent with base case, although differences between ziprasidone and haloperidol were slightly stronger. CONCLUSIONS: ziprasidone is associated with the lowest costs in the treatment of acute agitation episodes in schizophrenic patients in the Mexican setting, as well as better clinical performance than haloperidol.

PMH22
COST-UTILITY ANALYSIS OF DEPOT ATYPICAL ANTIPSYCHOTICS FOR CHRONIC SCHIZOPHRENIA IN CROATIA
Jukić V1, Jakovljević M2, Filipić H3, Hergert M4, Silic A4, Tomljanovic T5, Jensen R6
1Psychiatry hospital ‘Vrapce’, Zagreb, Croatia, 2University Hospital Zagreb, Zagreb, Croatia, 3Psychiatric Hospital Sveti Ivan, Zagreb, Croatia, 4Janssen Cilag, Birkerød, Denmark
OBJECTIVES: We conducted a pharmacoeconomic analysis to determine the cost-effectiveness of atypical antipsychotic long acting treatments in Croatia. METHODS: A 1-year decision-analytic framework model used drug use in chronic schizophrenia. We determined the average direct cost to the Croatian Institute for Health Insurance of using treatment pathways that includes depot formulations of paliperidone (PP-LAI), risperidone (RLAI) or olanzapine (OLZ-LAI) long acting treatments. The decision tree was populated with guidance from an expert panel along with literature-derived clinical rates. Costs were obtained from published lists and adjusted to 2012 euros using the Croatian consumer price index. Clinical outcomes included quality-adjusted life-years (QALYs), hospitalization rates, emergency room treatment rates, and relapse days. The outcome of interest was the incremental cost/QALY gained. RESULTS: Total direct costs per patient for one year were €4958 for PP-LAI, €6117 for RLAI and €6429 for OLZ-LAI. Relative QALYs were 0.817, 0.805 and 0.812. PP-LAI dominated the other choices as it had a lower cost and higher QALY score. PP-LAI was associated with 34.5 relapse days, 0.252 hospitalization and 0.127 emergency room visits; OLZ-LAI had 38.4 relapse days, 0.280 hospitalizations and 0.142 emergency room visits; RLAI had 41.1 relapse days, 0.305 hospitalizations and 0.146 emergency room visits. Results were sensitive against RLAI with respect to drug costs (i.e., if PP-LAI cost increased by 10% or RLZ-LAI decreased by 14%) and to OLZ-LAI (i.e., a 10% change for either drug with respect to adherence rates. Overall, results were generally robust; PP-LAI dominated OLZ-LAI in 72.2% of 10,000 Monte Carlo simulations and dominated RLZ-LAI in 87.8%. CONCLUSIONS: PP-LAI was the cost-effective choice which dominated the others for treating chronic schizophrenia in Croatia. Using depot haloperidol would reduce the overall costs of caring for SCI patients.

PMH23
A COST-EFFECTIVENESS ANALYSIS OF THE LONG-ACTING ATYPICAL DRUGS PALIPERIDONE PALMITATE, OLANZAPINE PAMOATE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN FINLAND
Kallioniemi T1, Pudas H2, Zilberstein R3, Jensen R4, Nielsen AT5, Ploko C6, Hemels M7, Vincente C8
1University of Toronto, Toronto, ON, Canada, 2Janssen, Espoo, Finland, 3Finnia Consulting Inc., Stockholm, Sweden, 4Janssen Cilag, Birkerød, Denmark, 5Psychiatric Hospital & University Hospital of Copenhagen, Copenhagen, Denmark, 6Psychiatry Hospital, Utrecht, The Netherlands, 7Frimois Institute, Utrecht, The Netherlands
OBJECTIVES: We determined the cost-effectiveness of long-acting antipsychotic (LA) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OLZ-LAI) and risperidone (RIS-LAI) for chronic schizophrenia. METHODS: We adapted a decision tree analysis from Norway for the Finnish National Health Service. Country-specific data were sought from the literature and public documents, guided by clinical experts. Costs of health services and products were retrieved from literature sources and current price lists. We estimated average costs for treating patients with each LAI for one year, average remission days, rates of hospitalization and